Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Eli Lilly Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (76)
Cancellation by sponsor (55)
Australian Public Assessment Report (AusPAR) (19)
Prescription medicine registration (16)
Designation or determination (4)
Prescription medicine decision summary (3)
Prescription medicine evaluation (3)

Date

2024 (23)
2023 (22)
2022 (15)
2021 (10)
2020 (4)
2019 (34)
2018 (14)
2017 (1)
2016 (2)
2015 (7)
2014 (2)
2013 (4)
2012 (1)
2011 (2)
2010 (1)
2008 (4)
2007 (3)
2006 (1)
2004 (7)
2003 (1)
2002 (2)
1999 (5)
1998 (1)
1996 (2)
1993 (1)
1992 (4)
1991 (3)

Results for "[search-keyword]"

Search

Sponsor content

176 result(s) found, displaying 61 to 70

HUMULIN R KWIKPEN biosynthetic human neutral insulin 100IU/mL injection multidose syringe Cancelled under Section 30(1)(c) of the Act

22 June 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
HUMULIN NPH KWIKPEN biosynthetic human isophane insulin 100IU/mL injection multidose syringe Cancelled under Section 30(1)(c) of the Act

22 June 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
HUMULIN 30/70 KWIKPEN biosynthetic human 30% neutral 70% isophane insulin 100IU/mL injection multidose syringe Cancelled under Section 30(1)(c) of the Act

22 June 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
TALTZ (Eli Lilly Australia Pty Ltd)

28 May 2021

Prescription medicine registration

Active ingredients: ixekizumab.
EFFIENT prasugrel (as hydrochloride) 5 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

20 May 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
EFFIENT prasugrel (as hydrochloride) 10 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

20 May 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
AusPAR: Baricitinib

5 May 2021

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Baricitinib
ANDEPRA duloxetine 60 mg (as hydrochloride) enteric capsule blister pack Cancelled under Section 30(1)(c) of the Act

14 May 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
ANDEPRA duloxetine 30 mg (as hydrochloride) enteric capsule blister pack Cancelled under Section 30(1)(c) of the Act

14 May 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
EMGALITY galcanezumab 120mg/mL prefilled syringe (302145)

28 May 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for EMGALITY galcanezumab 120mg/mL prefilled syringe.

Pages

First page
Previous page
…
Page 3
Page 4
Page 5
Page 6
Current page 7
Page 8
Page 9
Page 10
Page 11
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.